Download PDF
Semin Thromb Hemost 2007; 33(7): 712-721
DOI: 10.1055/s-2007-991540
© Thieme Medical Publishers

Inhibition of Platelet Function: Does It Offer a Chance of Better Cancer Progression Control?

Ewa Sierko1 , 2 , Marek Z. Wojtukiewicz1 , 2
  • 1Department of Oncology, Medical University, Bialystok, Poland
  • 2Comprehensive Cancer Center, Bialystok, Poland
Further Information

Publication History

Publication Date:
14 November 2007 (online)

    Permissions and Reprints

ABSTRACT

Thrombocytosis is frequently (10 to 57%) observed in cancer patients. Although the mechanisms underlying thrombocytosis are not yet fully elucidated, tumor-derived factors with thrombopoietin-like activity, growth factors, platelet-derived microparticles, and factors released from bone marrow endothelial cells as well as growth factors secreted by megakaryocytes (acting via an autocrine loop) are claimed to influence this process. The course of cancer is strongly associated with hypercoagulable state, which results from direct influences of tumor cells themselves and various indirect mechanisms. Activated platelets provide procoagulant surface amplifying the coagulation process. It is well documented that proteins of the hemostatic system influence different steps of metastasis, angiogenesis, and proteolytic events. Much less is known about the role of platelets in tumor growth and their possible contribution to prevention of tumor cells from the host immune system. Multidirectional activities of platelets during tumor development and metastatic dissemination create a possibility of introducing antiplatelet agents in anticancer therapy. The spectrum of plausible therapies includes antibodies against glycoprotein IIb-IIIa, direct thrombin inhibitors, protease activated receptor-1 targeted therapy, as well as cyclooxygenase (COX) and lipoxygenase (LOX) inhibitors. However, there is no sufficient information on a specific type of cancer where progression does depend on platelet function. Despite numerous experimental studies conducted, to date none of the new specific antiplatelet agents were tested in clinical trials in a cancer patient population.

KEYWORDS

Platelet inhibitors - cancer - metastasis - angiogenesis - proteolysis - immune surveillance

REFERENCES

  • 1 Francis J L, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy.  Semin Thromb Hemost. 1998;  24 93-109
    PubMedGoogle Scholar
  • 2 Zacharski L R, Wojtukiewicz M Z, Costantini V, Ornstein D L, Memoli V A. Pathways of coagulation/fibrinolysis activation in malignancy.  Semin Thromb Hemost. 1992;  18 104-116
    PubMedGoogle Scholar
  • 3 Rickles F R, Levine M, Edwards R L. Hemostatic alterations in cancer patients.  Cancer Metastasis Rev. 1992;  11 237-248
    CrossrefPubMedGoogle Scholar
  • 4 Sierko E, Wojtukiewicz M Z. Platelets and angiogenesis in malignancy.  Semin Thromb Hemost. 2004;  30 95-108
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Uppenkamp M, Makarove E, Petrasch S, Brittinger G. Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis.  Ann Hematol. 1998;  77 217-223
    CrossrefPubMedGoogle Scholar
  • 6 Kato N, Yasukawa K, Onozuka T, Kimura K. Paraneoplastic syndromes of leukocytosis, thrombocytosis, and hypercalcemia associated with squamous cell carcinoma.  J Dermatol. 1999;  26 352-358
    PubMedGoogle Scholar
  • 7 Estrov Z, Talpaz M, Mavlight G et al.. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis.  Am J Med. 1995;  98 551-558
    CrossrefPubMedGoogle Scholar
  • 8 Gastl G, Plante M, Finstad C L et al.. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.  Br J Haematol. 1993;  83 433-441
    PubMedGoogle Scholar
  • 9 Suzuki A, Takahashi T, Nakamura K et al.. Thrombocytosis in patients with tumors producing colony-stimulating factor.  Blood. 1992;  80 2052-2059
    PubMedGoogle Scholar
  • 10 Raffi S, Shapiro F, Pettengeli R et al.. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors.  Blood. 1995;  86 3353-3363
    PubMedGoogle Scholar
  • 11 Baj-Krzyworzeka M, Majka M, Pratico D et al.. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells.  Exp Hematol. 2002;  30 450-459
    CrossrefPubMedGoogle Scholar
  • 12 Schwarz R E. Platelet counts and prognosis of pancreatic cancer.  Lancet. 1999;  353 2158-2159
    PubMedGoogle Scholar
  • 13 Slichter S J, Harker L A. Hemostasis in malignancy.  Ann N Y Acad Sci. 1974;  230 252-262
    PubMedGoogle Scholar
  • 14 Tang D G, Honn K V. Adhesion molecules and tumor metastasis: an update.  Invasion Metastasis. 1994-95;  14 109-122
    PubMedGoogle Scholar
  • 15 Honn K V, Tang G T, Chen Y Q. Platelets and cancer metastasis: more than an epiphenomenon.  Semin Thromb Hemost. 1992;  18 392-415
    PubMedGoogle Scholar
  • 16 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases.  Nat Med. 1995;  1 27-31
    CrossrefPubMedGoogle Scholar
  • 17 Wojtukiewicz M Z, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy.  Neoplasia. 2001;  3 371-384
    Google Scholar
  • 18 Wojtukiewicz M Z, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer.  Semin Thromb Hemost. 2004;  30 5-20
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Timár J, Tówári J, Rásó E, Mèszáros L. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance.  Oncology. 2005;  69 185-201
    CrossrefPubMedGoogle Scholar
  • 20 Heemskerk J WM, Bevers E M, Lindhout T. Platelet activation and blood coagulation.  Thromb Haemost. 2002;  88 186-193
    PubMedGoogle Scholar
  • 21 Andrews R K, Shen Y, Gardiner E E, Berndt M C. Platelet adhesion receptors and (patho)physiological thrombus formation.  Histol Histopathol. 2001;  16 969-980
    PubMedGoogle Scholar
  • 22 Chen H, Locke D, Liu Y, Kahn M L. The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion.  J Biol Chem. 2002;  277 3011-3019
    CrossrefPubMedGoogle Scholar
  • 23 Kamata T, Takada Y. Platelet integrin alphaIIbbeta3-ligand interactions: what we learn from the structure?.  Int J Hematol. 2001;  74 382-389
    PubMedGoogle Scholar
  • 24 Coughlin S R. Protease-activated receptors and platelet function.  Thromb Haemost. 1999;  82 353-356
    PubMedGoogle Scholar
  • 25 Di Virgilio F, Chiozzi P, Ferrari D et al.. Nucleotide receptors: an emerging family of regulatory molecules in blood cells.  Blood. 2001;  97 587-600
    CrossrefPubMedGoogle Scholar
  • 26 Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions.  Platelets. 2001;  12 261-273
    CrossrefPubMedGoogle Scholar
  • 27 Wehmeier A, Tschope D, Esser J et al.. Circulating activated platelets in myeloproliferative disorders.  Thromb Res. 1991;  61 271-278
    CrossrefPubMedGoogle Scholar
  • 28 Blann A D, Gurney M, Wadley D, Bareford D, Stonelake P, Lip G Y. Increased soluble P-selectin in patients with hematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor.  Blood Coagul Fibrinolysis. 2001;  12 43-50
    CrossrefPubMedGoogle Scholar
  • 29 Caine G J, Lip G Y, Stonelake P S, Ryan P, Blann A D. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma.  Thromb Haemost. 2004;  92 185-190
    PubMedGoogle Scholar
  • 30 Karpatkin S, Nierodzik M L, Klepfish A. Role of platelets, thrombin in cancer.  Vessels. 1996;  2 17-23
    PubMedGoogle Scholar
  • 31 Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient.  Semin Thromb Hemost. 1999;  25 173-182
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Yu J L, Rak J W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the mein source of TF activity released from human cancer cells.  J Thromb Haemost. 2004;  2 2065-2067
    Google Scholar
  • 33 Nomura S, Fukuhara S. Platelet microparticles.  Methods Mol Biol. 2004;  272 269-277
    PubMedGoogle Scholar
  • 34 Kitagawa H, Yamamoto N, Yamamoto K et al.. Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells.  Cancer Res. 1989;  49 537-541
    PubMedGoogle Scholar
  • 35 Hejna M, Raderer M, Zielinsky C C. Inhibition of metastasis by anticoagulants.  J Natl Cancer Inst. 1999;  91 22-36
    CrossrefPubMedGoogle Scholar
  • 36 Gasic G J, Gasic T B, Steward C C. Antimetastatic effects associated with platelet reduction.  Proc Natl Acad Sci USA. 1968;  61 46-52
    PubMedGoogle Scholar
  • 37 Nierodzik M L, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo.  Thromb Haemost. 1995;  74 282-290
    PubMedGoogle Scholar
  • 38 McCarty O J, Mouse S A, Bray P F, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions.  Blood. 2000;  96 1789-1797
    PubMedGoogle Scholar
  • 39 Felding-Habermann B. Tumor cell-platelet interaction in metastatic disease.  Haemostasis. 2000;  31(Suppl 1) 55-58
    PubMedGoogle Scholar
  • 40 Chopra H, Timar J, Rong X et al.. Is there a role for the tumor cell integrin αIIbß3 in tumor-cell induced platelet aggregation.  Clin Exp Metastasis. 1992;  10 125-137
    CrossrefPubMedGoogle Scholar
  • 41 Steinert B W, Tang D G, Grossi I M, Umbarger L A, Honn K V. Studies on the role of platelet eicosanoid metabolism and integrin αIIbß3in tumor-cell-induced platelet aggregation.  Int J Cancer. 1993;  54 92-101
    PubMedGoogle Scholar
  • 42 Lip G YH, Chin B SP, Blann A D. Cancer and the prothrombotic state.  Lancet Oncol. 2002;  3 27-34
    CrossrefPubMedGoogle Scholar
  • 43 Nash G F, Turner L F, Schully M F, Kakkar A K. Platelets and cancer.  Lancet Oncol. 2002;  3 425-430
    CrossrefPubMedGoogle Scholar
  • 44 Pasqualini M E, Mohn C E, Petiti J P, Manzo P, Eynard A R. COX and LOX eicosanoids modulate platelet activation and procoagulation induced by two murine cancer cells.  Prostaglandins Leukot Essent Fatty Acids. 2000;  63 377-383
    CrossrefPubMedGoogle Scholar
  • 45 Boucharaba A, Serre C-M, Grès S et al.. Platelet-derived lysophosphatic acid supports the progression of osteolytic bone metastases in breast cancer.  J Clin Invest. 2004;  114 1714-1725
    CrossrefPubMedGoogle Scholar
  • 46 Belloc C, Lu H, Soria C et al.. The effect of platelets on invasiveness and protease production of human mammary tumor cells.  Int J Cancer. 1995;  60 413-417
    PubMedGoogle Scholar
  • 47 Verheul H MW, Hoekman K, Lupu F et al.. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.  Clin Cancer Res. 2000;  6 166-171
    PubMedGoogle Scholar
  • 48 Ischii L, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology.  Annu Rev Biochem. 2004;  73 321-354
    CrossrefPubMedGoogle Scholar
  • 49 Van Corven E J, Groenink A, Jalink K, Eicholtz T, Moolenaar W H. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins.  Cell. 1989;  59 45-54
    CrossrefPubMedGoogle Scholar
  • 50 Möhle R, Green D, Moore M A, Nachman R L, Rafii S. Constitutive production and thrombin-induced relaease of vascular endothelial growth factor by human megakaryocytes and platelets.  Proc Natl Acad Sci USA. 1997;  94 663-668
    CrossrefPubMedGoogle Scholar
  • 51 Salgado R, Vermeulen P B, Benoy I et al.. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.  Br J Cancer. 1999;  80 892-897
    CrossrefPubMedGoogle Scholar
  • 52 Verheul H MW, Hoekman K, Luykx-de Bakker S et al.. Platelet transporter of vascular endothelial growth factor.  Clin Cancer Res. 1997;  3 2187-2190
    PubMedGoogle Scholar
  • 53 Wartiovaara U, Salven P, Mikkola Heta I. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.  Thromb Haemost. 1998;  80 171-175
    PubMedGoogle Scholar
  • 54 Ohm J E, Carbone D P. VEGF as a mediator of tumor-associated immunodeficiency.  Immunol Res. 2001;  23 263-272
    CrossrefPubMedGoogle Scholar
  • 55 Yang L, Carbone D P. Tumor-host immune interactions and dendritic cell dysfunction.  Adv Cancer Res. 2004;  92 13-27
    PubMedGoogle Scholar
  • 56 Nieswandt B, Hafner M, Echtenacher B, Männel D N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets.  Cancer Res. 1999;  59 1295-1300
    PubMedGoogle Scholar
  • 57 Folkman J. Tumor angiogenesis: therapeutic implications.  N Engl J Med. 1971;  285 1182-1186
    CrossrefPubMedGoogle Scholar
  • 58 Verheul H M, Jorna A S, Hoekman K et al.. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets.  Blood. 2000;  96 4216-4221
    PubMedGoogle Scholar
  • 59 Pipili-Synetos E, Papadimitriou E, Maragoudakis M E. Evidence that platelets promote tube formation by endothelial cells on matrigel.  Br J Pharmacol. 1998;  125 1252-1257
    CrossrefPubMedGoogle Scholar
  • 60 Kisucka J, Butterfield C E, Duda D G et al.. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage.  Proc Natl Acad Sci USA. 2006;  103 855-860
    CrossrefPubMedGoogle Scholar
  • 61 Rhee J S, Black M, Schubert U et al.. The functional role of blood platelet components in angiogenesis.  Thromb Haemost. 2004;  92 394-402
    PubMedGoogle Scholar
  • 62 Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimmulate post-ischaemic revascularization.  Cardiovasc Res. 2005;  67 30-38
    CrossrefPubMedGoogle Scholar
  • 63 McDowell G, Temple I, Li C et al.. Alteration in platelet function in patients with early breast cancer.  Anticancer Res. 2005;  25 3963-3966
    PubMedGoogle Scholar
  • 64 Werther K, Chjritensen I J, Nielsen H J. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets.  Scand J Clin Lab Invest. 2002;  62 343-350
    CrossrefPubMedGoogle Scholar
  • 65 Kim S J, Choi I K, Park K H et al.. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival.  Jpn J Clin Oncol. 2004;  34 184-190
    CrossrefPubMedGoogle Scholar
  • 66 Ma L, Perini R, McKnight W, Klein A, Hollenberg M D, Wallace J L. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.  Proc Natl Acad Sci USA. 2005;  102 216-220
    CrossrefPubMedGoogle Scholar
  • 67 Brock T A, Dvorak H F, Senger D R. Tumour secreted vascular permeability factor increases cytosolic Ca2 + and von Willebrand factor release in human cells.  Am J Pathol. 1991;  138 213-221
    PubMedGoogle Scholar
  • 68 Thurston G, Rudge J S, Ioffe E et al.. Angiopoietin-1 protects the adult vasculature against leakage.  Nat Med. 2000;  6 460-463
    CrossrefPubMedGoogle Scholar
  • 69 Clauss M, Gerlach M, Gerlach H et al.. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.  J Exp Med. 1990;  172 1535-1545
    CrossrefPubMedGoogle Scholar
  • 70 Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling.  Thromb Haemost. 1999;  82 748-754
    PubMedGoogle Scholar
  • 71 Valter M M, Wietler O D, Pietsche T, Pietsch T. Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF.  Int J Dev Neurosci. 1999;  17 565-577
    PubMedGoogle Scholar
  • 72 Guo P, Gu W, Xu L et al.. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.  Am J Pathol. 2003;  162 1083-1093
    PubMedGoogle Scholar
  • 73 Tomita N, Morishita R, Taniyama Y et al.. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis ets-1.  Circulation. 2003;  107 1411-1417
    CrossrefPubMedGoogle Scholar
  • 74 Lee O H, Bae S K, Bae M H et al.. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models.  Br J Cancer. 2000;  82 385-391
    CrossrefPubMedGoogle Scholar
  • 75 Dunn S E, Tores J V, Nihei N, Barrett J C. The insulin growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy.  Mol Carcinog. 2000;  27 10-17
    CrossrefPubMedGoogle Scholar
  • 76 Breier G, Blum S, Peli J et al.. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis.  Int J Cancer. 2002;  97 142-148
    CrossrefPubMedGoogle Scholar
  • 77 Davis S, Yancopoulos G D. Yin and yang in angiogenesis.  Curr Top Microbiol Immunol. 1999;  237 173-185
    PubMedGoogle Scholar
  • 78 McMahon G A, Petitclerc E, Stefansson S et al.. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.  J Biol Chem. 2001;  276 33964-33968
    CrossrefPubMedGoogle Scholar
  • 79 VanWijk M J, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases.  Cardiovasc Res. 2003;  59 277-287
    CrossrefPubMedGoogle Scholar
  • 80 Teuscher E, Weidlich V. Adenosine nucleotides, adenosine and adenine as angiogenesis factors.  Biomed Biochim Acta. 1985;  44 493-495
    PubMedGoogle Scholar
  • 81 English D, Welch Z, Kovala A T et al.. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis.  FASEB J. 2000;  14 2255-2265
    CrossrefPubMedGoogle Scholar
  • 82 Freyssinet J M. Cellular microparticles: what are they bad or good for?.  J Thromb Haemost. 2003;  1 1655-1662
    CrossrefPubMedGoogle Scholar
  • 83 Janowska-Wieczorek A, Wysoczynski M, Kijowski J et al.. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer.  Int J Cancer. 2005;  113 752-760
    CrossrefPubMedGoogle Scholar
  • 84 Good D J, Polverini P J, Rastinejad F et al.. A tumor supprressor-dependent inhibitor of angiogenesis is immunologically and functionally indistiguishable from a fragment of thrombospondin.  Proc Natl Acad Sci USA. 1990;  87 6624-6628
    PubMedGoogle Scholar
  • 85 Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis.  Nature. 1982;  297 307-312
    CrossrefPubMedGoogle Scholar
  • 86 Nakabayashi M, Morishita R, Nakagami H et al.. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.  Diabetologia. 2003;  46 115-123
    PubMedGoogle Scholar
  • 87 Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production.  Br J Pharmacol. 2003;  139 329-336
    CrossrefPubMedGoogle Scholar
  • 88 Jurasz P, Santos-Martinez M J, Radomska A, Radomski M W. Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis.  J Thromb Haemost. 2006;  4 1095-1106
    CrossrefPubMedGoogle Scholar
  • 89 Sawicki G, Salas E, Murat J et al.. Release of gelatinase A during platelet activation mediates aggregation.  Nature. 1997;  386 616-619
    CrossrefPubMedGoogle Scholar
  • 90 Menashi S, He L, Soria C et al.. Modulation of endothelial cells fibrinolytic activity by platelets.  Thromb Haemost. 1991;  65 77-81
    PubMedGoogle Scholar
  • 91 Huang S, Van Arsdall M, Tedjarati S et al.. Contribution of stromal metalloproteinase 9 to angiogenesis and growth of human ovarian carcinoma in mice.  J Natl Cancer Inst. 2002;  94 1134-1142
    PubMedGoogle Scholar
  • 92 Kazes I, Elalamy I, Sraer J D et al.. Platelet release of trimolecular complex components MT1-TIMP2-MMP2: involvement in MMP2 activation and platelet aggregation.  Blood. 2000;  96 3064-3069
    PubMedGoogle Scholar
  • 93 Vlodavsky I, Eldor A, Haimovitz-Friedman A et al.. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.  Invasion Metastasis. 1992;  12 112-127
    PubMedGoogle Scholar
  • 94 Coller B S, Peerschke E L, Scudder L E, Sullivan C A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombastenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.  J Clin Invest. 1983;  72 325-328
    CrossrefPubMedGoogle Scholar
  • 95 Coller B S. Anti-GpIIb/IIIa drugs: current strategies and future directions.  Thromb Haemost. 2001;  86 427-443
    PubMedGoogle Scholar
  • 96 Trikha M, Zhou Z, Timar J et al.. Multiple roles for platelet GPIIb/IIa and platelet alpha v beta 3 integrins in tumor growth, angiogenesis, and metastasis.  Cancer Res. 2002;  62 2824-2833
    PubMedGoogle Scholar
  • 97 Amirkhosravi A, Amaya M, Siddiqui F et al.. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor-cell-activated platelets and experimental metastasis.  Platelets. 1999;  10 285-292
    CrossrefPubMedGoogle Scholar
  • 98 Trikha M, Zhou Z, Jordan J, Nakada M T. ReoPro and m7E3 F(ab')2 inhibit β3 integrin mediated tumor growh and angiogenesis.  [abstract] Proc Am Assoc Cancer Res. 2000;  42 824
    PubMedGoogle Scholar
  • 99 Engelberg H. Actions of heparins that may affect the malignant process.  Cancer. 1999;  85 257-272
    CrossrefPubMedGoogle Scholar
  • 100 Amirkhosravi A, Mousa S A, Amaya M et al.. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb-IIIa antagonist XV454.  Thromb Haemost. 2003;  90 549-554
    PubMedGoogle Scholar
  • 101 Sheu J R, Lin C H, Chung Jl, Teng C M, Huang T F. Triflavin, an Arg-Gly-Asp containing snake venom peptide, inhibits aggregation of human platelets induced by human hepatoma cell line.  Thromb Res. 1992;  66 679-691
    CrossrefPubMedGoogle Scholar
  • 102 Chiang H S, Swaim M W, Huang T F. Characterization of platelet aggregation induced by human colon adenocarcinoma cells and its inhibition by snake venom peptides, trigramin and rhodostomin.  Br J Haematol. 1994;  87 325-331
    PubMedGoogle Scholar
  • 103 Chiang H S, Swaim M W, Huang T F. The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells.  Br J Cancer. 1995;  71 265-270
    PubMedGoogle Scholar
  • 104 Chiang H S, Swaim M W, Huang T F. Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin.  Breast Cancer Res Treat. 1995;  33 225-235
    CrossrefPubMedGoogle Scholar
  • 105 Lever R, Page C P. Novel drug development opportunities for heparin.  Nat Rev Drug Discov. 2002;  1 140-148
    CrossrefPubMedGoogle Scholar
  • 106 da Silva M S, Horton J A, Wijelath J M et al.. Heparin modulates integrin-mediated cellular adhesion: specificity of interaction with alpha and beta integrin subunits.  Cell Adhes Commun. 2003;  10 59-67
    PubMedGoogle Scholar
  • 107 Borsig L, Wong R, Feramisco J et al.. Heparin and cancer revised: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.  Proc Natl Acad Sci USA. 2001;  98 3352-3357
    CrossrefPubMedGoogle Scholar
  • 108 Ludwig R J, Beohme B, Podda M et al.. Endothelial P-selectin as a target of heparinb action in experimental melanoma lung metastasis.  Cancer Res. 2004;  64 2743-2750
    CrossrefPubMedGoogle Scholar
  • 109 Kakkar A K. Low molecular weight heparin and survival in cancer.  Haematological Rep. 2005;  1 27
    PubMedGoogle Scholar
  • 110 Butenas S, Cawthern K, Veer C et al.. Antiplatelet agents in tissue factor-induced blood coagulation.  Blood. 2001;  97 2314-2322
    CrossrefPubMedGoogle Scholar
  • 111 Waltermann A, Wolzt M, Petersmann K et al.. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo.  Arterioscler Thromb Vasc Biol. 1999;  19 1757-1760
    PubMedGoogle Scholar
  • 112 Gasic G J, Gasic T B, Stewart C C. Antimetastatic effect associated with platelet reduction.  Proc Natl Acad Sci USA. 1968;  61 46-52
    PubMedGoogle Scholar
  • 113 Sheu J R, Lin C H, Pung H C, Teng C M, Huang T F. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation.  Jpn J Cancer Res. 1993;  84 1062-1071
    PubMedGoogle Scholar
  • 114 Damiano B P, Derian C K, Maryanoff B E, Zhang H C, Gordon P A. RWJ-58259: a selective antagonists of protease activated receptor-1.  Cardiovasc Drug Rev. 2003;  21 313-326
    PubMedGoogle Scholar
  • 115 Shi X, Gangedharan B, Brass L F, Ruf W, Mueller B M. Protease-activated receptors (PAR-1 and PAR-2) contribute to tumor cell motility and metastasis.  Mol Cancer Res. 2004;  2 395-402
    PubMedGoogle Scholar
  • 116 Zania P, Kritikou S, Flordellis C S, Maragoudakis M E, Tsopanoglou N E. Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis.  J Pharmacol Exp Ther. 2006;  318 246-254
    CrossrefPubMedGoogle Scholar
  • 117 Nash G F, Walsh D C, Kakkar A K. The role of the coagulation system in tumour angiogemesis.  Lancet Oncol. 2001;  2 608-613
    CrossrefPubMedGoogle Scholar
  • 118 Nigam S, Zakrzewic A, Eskafi S, Roscher A. Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract.  Cancer Metastasis Rev. 1992;  11 411-420
    CrossrefPubMedGoogle Scholar
  • 119 Nie D, Che M, Zacharek A et al.. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility.  Am J Pathol. 2004;  164 429-439
    PubMedGoogle Scholar
  • 120 Honn K V, Tang D G, Butovich I A, Liu B, Timar J, Hagmann W. 12-lipooxygenases and 12(S)-HETE: role in cancer metastasis.  Cancer Metastasis Rev. 1994;  13 365-366
    CrossrefPubMedGoogle Scholar
  • 121 Tang D G, Li L, Zhu Z et al.. BMD188, a novel hydroxamic acid compound, demonstrates potent an prostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases.  Pathol Oncol Res. 1998;  4 179-190
    PubMedGoogle Scholar
  • 122 Gasic G J, Gasic T B, Galanti N, Johnson T, Murphy S. Platelet tumor interactions in mice. The role of platelets in spread of malignant diseases.  Int J Cancer. 1973;  11 704-718
    CrossrefPubMedGoogle Scholar
  • 123 Wood Jr S, Hilgard P. Aspirin and tumor metastasis.  Lancet. 1972;  2 1416-1417
    PubMedGoogle Scholar
  • 124 Mamytbeková A, Rezábek K, Kacerovská H, Grimová J, Svobodová J. Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors.  Neoplasma. 1986;  33 417-421
    PubMedGoogle Scholar
  • 125 Mehta P, Lawson D, Ward M B, Lee-Ambrose L, Kimura A. Effect of tromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation.  Cancer Res. 1986;  46 5061-5063
    PubMedGoogle Scholar
  • 126 Bando H, Yamashita T, Tsubura E. Effects of antiplatelet agents on pulmonary metastases.  Gann. 1984;  75 284-291
    PubMedGoogle Scholar
  • 127 Mussoni L, Poggi A, De Gaetano G, Donati M B. Effect of diltazole, an inhibitor of platelet aggregation, on a metastasizing tumor in mice.  Br J Cancer. 1978;  37 126-129
    PubMedGoogle Scholar
  • 128 Hilgard P, Heller H, Schmidt C G. The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL).  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1976;  86 243-250
    PubMedGoogle Scholar
  • 129 Lichtner R B, Hutchinson G, Wedderburn N, Hellmann K. Antiplatelet pyrimido-pyrimidines and metastasis.  Cancer Treat Rev. 1985;  12 221-234
    CrossrefPubMedGoogle Scholar
  • 130 Lichtner R B, Hutchinson G, Hellmann K. The pyrimido-pyrimidines derivatives RA233 and RX-RA85 affect cell cycle distribution of two murine tumour cell lines.  Eur J Cancer Clin Oncol. 1989;  25 945-951
    CrossrefPubMedGoogle Scholar
  • 131 Stackpole C W, Fornabaio D M, Alterman A L. Failure of orally administered RA233 to influence B16 melanoma growth or metastasis.  Clin Exp Metastasis. 1987;  5 165-180
    PubMedGoogle Scholar
  • 132 Li X T, Hellmann K. Effect of DRA233 alone and combined with radiation on experimental tumour metastasis. Part 1.  Clin Exp Metastasis. 1983;  1 51-59
    PubMedGoogle Scholar
  • 133 Gastpar H. Modification of metastasis formation by inhibition of platelet aggregation. Experimental and clinical results.  Laryngol Rhinol Otol (Stuttg). 1983;  62 578-585
    PubMedGoogle Scholar
  • 134 Kohga S, Kinjo M, Tanaka K, Ogawa H, Ishihara M, Tanaka N. Effects of 5-(2-chlorobenzyl)-4,5,6,7,-tetrahydrothieno[3,2-C]pyridine hydrochloride (ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.  Cancer Res. 1981;  41 4710-4714
    PubMedGoogle Scholar
  • 135 Fabra A, de Castellarnau C, Carretero F, Martinez E, Sancho M J, Rutllant M L. Effects of ticlopidine on metastasis production in mice bearing Lewis lung carcinoma.  Invasion Metastasis. 1987;  7 53-60
    PubMedGoogle Scholar

Ewa SierkoM.D. 

Department of Oncology, Medical University

12 Ogrodowa St., 15-027 Bialystok, Poland

Email: ewa.sierko@iq.pl

      >